NCT06614062Completed
Clinical Study of 18F-FAPI-RGD in Ovarian Cancer
Clinical Study of 18F Labeled Probe Targeting Fibroblast Activation Protein Inhibitor and Integrin Avβ3 (FAPI-RGD) in Ovarian Cancer,comparison with 18F-FDG
Source: ClinicalTrials.gov · Last updated 26 Sept 2024
Brief summary (registry, in English)
The goal of this observational study is to learn about the value of 18F-FAPI-RGD PET/CT imaging in ovarian cancer. Participants will undergo clinical evaluation and 18F-FAPI-RGD PET/CT examination and compare it with 18F-FDG PET/CT imaging.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 30 (actual)
- First submitted
- 23 Sept 2024
- Start date
- 1 Dec 2023
- Primary completion date
- 30 Aug 2024
- Lead sponsor
- Sichuan Provincial People's Hospital
- Diseases
- Ovarian cancer
- NCT number
- NCT06614062
What you commit to
- Study type: Observational
- Participants enrolled: 30
- From 1 Dec 2023 to the primary completion date, 30 Aug 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \-
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Departments of Nuclear Medicine Coordinator of this site? Confirm its status | Chengdu | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.